What is treatment for children and teens with schizophrenia, and how does it work?
Treatment for children and teens with schizophrenia is a long-term, multi-component programme that combines antipsychotic medication, individual and family psychotherapy, educational support and regular psychiatric monitoring. Schizophrenia in childhood (onset before 13) and adolescence (onset between 13 and 18) is clinically distinct from the adult form: symptoms — which include hallucinations, delusions, disorganised thinking, blunted affect and social withdrawal — tend to emerge more gradually and can be harder to distinguish from normal developmental changes. Diagnosis requires a thorough assessment by a child and adolescent psychiatrist and must rule out other conditions such as bipolar disorder, severe depression with psychotic features and substance-related psychosis. This guide explains how the combined approach works, what the evidence shows, what it costs compared with the UK, US and Germany, and how families can evaluate a specialist psychiatric clinic. For the wider range of psychiatry treatments in Turkey, see our hub page.
How do antipsychotic medications work in young patients?
Second-generation (atypical) antipsychotics are the first-line pharmacological choice for early-onset schizophrenia according to guidelines from the American Academy of Child and Adolescent Psychiatry (AACAP) and NICE. Drugs such as risperidone, aripiprazole, olanzapine and quetiapine act primarily by modulating dopamine and serotonin pathways, reducing positive symptoms — hallucinations and delusions — in a majority of young patients within four to six weeks of reaching a therapeutic dose. Negative symptoms (flat affect, reduced motivation, social withdrawal) and cognitive difficulties tend to respond more slowly and less completely. Because children and adolescents are more sensitive than adults to certain side effects — including weight gain, metabolic changes and extrapyramidal effects — the prescribing psychiatrist monitors weight, blood glucose, lipids and movement symptoms at regular intervals, usually every three months once stable. Medication is not taken in isolation; it is always combined with psychosocial support.
What does the psychosocial programme include?
Medication reduces acute symptoms; psychosocial therapies help the young person and family rebuild functioning and prevent relapse. A specialist programme typically includes:
- Individual cognitive behavioural therapy for psychosis (CBTp): adapted for age, it helps the young person understand and manage their symptoms, test delusional beliefs and develop coping strategies.
- Family psychoeducation and therapy: evidence shows that high expressed emotion in the family is a strong predictor of relapse; structured family intervention reduces relapse rates and improves carers' wellbeing. Sessions are delivered over several months.
- Social skills training: role-play and group sessions to rebuild the peer and communication skills that the illness may have disrupted.
- Educational liaison: close work with the young person's school or college to arrange adapted learning, reduced workload during acute phases and gradual reintegration.
- Occupational and vocational support: for older teenagers, structured activity helps with daily functioning and long-term independence.
Coordinated early intervention programmes that bring these elements together are associated with better outcomes than medication alone, and are now standard in specialist child and adolescent mental health services (CAMHS) in many countries. For families considering psychotherapy as part of a broader psychiatric package, our guide explains what individual and family therapy involves.
Does treatment actually work? What does the evidence say?
Antipsychotic medication reduces positive symptoms in around 60–70 % of children and adolescents with schizophrenia, according to data reviewed by the AACAP and published in journals including the Journal of the American Academy of Child and Adolescent Psychiatry. Early treatment — within the first episode and before the duration of untreated psychosis extends — is consistently associated with better long-term outcomes in terms of symptom control, social functioning and educational attainment. Family psychoeducation programmes reduce relapse rates by roughly a third compared with medication alone, based on the Cochrane reviews of family intervention in psychosis.
What the evidence does not support: schizophrenia in young people is a serious, long-term condition and no treatment programme offers a cure. Some young people achieve sustained remission on medication with minimal side effects; others have a more episodic or persistent course requiring multiple medication adjustments. Cognitive impairments — attention, memory and processing speed — often persist even when positive symptoms are controlled, and may need specific educational accommodations. A trustworthy programme will explain the realistic range of outcomes rather than promise full recovery.
Approximate cost of treatment in Turkey compared with the UK, US and Germany
Costs vary considerably depending on whether the admission is inpatient or outpatient, the duration of the programme, the number of therapy sessions included, and the diagnostic workup required. The figures below are approximate ranges for a structured programme (initial inpatient stabilisation if required plus an outpatient psychosocial package); they are not quotes from individual hospitals. Each facility will confirm its own pricing in a written plan.
| Country | Approximate cost range |
|---|---|
| Turkey | €2,500 – €10,000 |
| United Kingdom | €8,000 – €30,000+ |
| United States | €12,000 – €50,000+ |
| Germany | €7,000 – €25,000 |
What changes the price: inpatient versus outpatient care; length of stay (days to weeks); whether neuropsychological testing, MRI brain imaging or electroencephalography (EEG) are included in the diagnostic phase; the number of included therapy sessions; and whether the package covers follow-up consultations after discharge. A written package outline should itemise what is and is not included. Request a free written quote to compare options before making any commitment.
Who is a suitable candidate, and when is specialist care abroad appropriate?
Specialist inpatient or intensive outpatient programmes abroad may be considered when waiting times for child and adolescent psychiatric services at home are long, when a first episode has not responded to an initial medication trial and a second opinion from an experienced team is needed, or when the family needs an intensive family therapy component that is not available locally. Young people most likely to benefit from an organised specialist programme are those in the early stages of illness, with active positive symptoms that have not yet been treated, or those who have had one or two episodes and whose current treatment is not preventing relapse.
Specialist inpatient psychiatric care abroad is not appropriate as an emergency intervention for an acutely psychotic or agitated young person who needs immediate crisis management; that must be handled by services in the home country. It is also not appropriate if the young person is unwilling to engage with treatment or travel, as motivation and therapeutic alliance are prerequisites for the psychosocial components to work.
What does a treatment programme look like, step by step?
A structured programme for a young person with schizophrenia typically proceeds as follows:
- Pre-admission assessment: the psychiatric team reviews existing reports, previous medication trials and school records; a video consultation is usually arranged before travel to establish rapport and confirm suitability.
- Diagnostic workup (days 1–3): comprehensive psychiatric assessment, neuropsychological testing, blood tests, ECG and, where indicated, MRI brain imaging or EEG to rule out organic causes.
- Medication review and adjustment (ongoing from day 1): if the young person is already on medication, the team reviews the choice and dose; if starting treatment, the medication is introduced gradually with daily monitoring of response and side effects.
- Individual therapy sessions (daily or several times per week): CBTp adapted for the young person's age, cognitive level and symptom profile.
- Family sessions (several times per week): psychoeducation, communication training and relapse-prevention planning with parents and siblings.
- Group activities and skills training: structured daily programme to maintain routine, rebuild social confidence and reduce isolation.
- Discharge planning and aftercare coordination: a written treatment summary and relapse plan is prepared for the home psychiatric team; a follow-up video consultation is typically scheduled at four to six weeks after discharge.
How long is the stay and what does recovery look like over time?
For families travelling to Turkey, an initial inpatient stabilisation programme is usually two to four weeks; some clinics offer a ten- to fourteen-day intensive outpatient programme for young people who are already partially stabilised on medication. Acute positive symptoms — hallucinations and delusions — typically begin to reduce within two to six weeks of starting or adjusting medication. Social withdrawal and negative symptoms may take several months to improve, and cognitive difficulties may require longer-term educational support.
Recovery milestones for early-onset schizophrenia treatment tend to follow a pattern: reduced frequency and intensity of psychotic episodes over the first six months; gradual return to school or college with accommodations over months two to twelve; and ongoing monitoring with medication reviews every three to six months thereafter. Relapse is a risk, particularly during adolescence when neurological development is still occurring; a written relapse plan agreed with the family is therefore a core part of discharge. The aftercare coordination between the Turkish team and the family's local CAMHS service is as important as the in-person programme itself.
Comparison: antipsychotic-led, integrated and CBTp-focused approaches
Families are sometimes uncertain whether to prioritise medication, therapy or an integrated model. The table below summarises the three main approaches, their strengths and their limitations.
| Approach | Best suited to | Typical limits |
|---|---|---|
| Medication-led (antipsychotic only) | Acute stabilisation; first episode with severe positive symptoms | Does not address negative symptoms, cognitive difficulties or family stress without additional support |
| Integrated early intervention (medication + CBTp + family therapy) | First and second episode; motivated young person with family support | Requires sustained engagement over months; needs an experienced multidisciplinary team |
| CBTp-focused (therapy-primary, low or no medication) | Mild presentations; young people or families wishing to minimise medication | Not suitable for acute or severe psychosis; evidence base is weaker for children than adults |
Most specialist centres follow the integrated model as it has the strongest evidence base for young people. Where medication is unavoidable, the choice of drug and dose is tailored to the individual, taking into account weight, metabolic risk and previous response. For information on how our clinic-matching process works, see how it works.
Risks, side effects and safeguarding considerations
Antipsychotic medications in children and adolescents carry a range of potential side effects that require active monitoring. Common effects include sedation, weight gain and increased appetite, particularly with olanzapine and quetiapine. Metabolic effects — raised blood glucose and lipids — are monitored with regular blood tests. Extrapyramidal effects (restlessness, stiffness, involuntary movements) are more common with higher-potency drugs and are managed by dose adjustment or switching. Prolongation of the QTc interval on ECG is a rare but serious cardiac risk, and a baseline ECG is standard before starting treatment.
Safeguarding is a specific consideration when treating minors: any programme must have clear consent protocols for the young person and their legal guardians, a named lead clinician responsible for the child's care, and documented procedures for involving local statutory services if welfare concerns arise. The Royal College of Psychiatrists and AACAP both publish standards for inpatient care of young people with psychosis that a reputable facility should be able to demonstrate compliance with. Ask the clinic how they handle situations where the young person becomes unwilling to continue treatment during the admission.
How to evaluate a psychiatric clinic and questions to ask
When comparing psychiatric facilities for a child or teenager with schizophrenia, check that the team includes a child and adolescent psychiatrist (not only adult psychiatrists), that the inpatient unit is specifically designed for young people (or has a dedicated adolescent section), and that the programme includes both individual and family therapy rather than medication review alone. Ask for a written treatment plan before any payment. Red flags include facilities that cannot name the lead clinician for your child, that offer no family involvement, that give a prognosis without first reviewing the records, or that pressure you to book without a preparatory assessment. Our process connects families with verified psychiatric facilities and provides a written plan before commitment; you can start with a free quote.
Questions to ask the clinic before booking:
- Who is the named child and adolescent psychiatrist, and what is their training and experience with early-onset schizophrenia?
- Is the inpatient unit exclusively or predominantly for young people?
- How many therapy sessions (individual and family) are included per week?
- What monitoring is in place for medication side effects, particularly metabolic and cardiac?
- What is the protocol if my child's condition deteriorates during the admission?
- How will you coordinate with our home psychiatric team after discharge?
- Can we have a video consultation with the lead psychiatrist before we travel?
Conditions treated with Treatment for Children and Teens with Schizophrenia
Hospitals with Psychiatry & Addiction in Turkey
Frequently asked questions
It is a long-term programme combining antipsychotic medication, individual cognitive behavioural therapy adapted for young people, family psychoeducation, social skills training and educational support. The goal is to reduce symptoms, prevent relapse and help the young person maintain development and schooling as far as possible.
Antipsychotic medication reduces positive symptoms such as hallucinations and delusions in around 60–70% of young patients. Integrated programmes that add family therapy and CBTp further reduce relapse risk. Schizophrenia is a long-term condition; treatment manages rather than cures it, and outcomes vary between individuals.
Approximate costs in Turkey range from €2,500 to €10,000 for a structured programme, compared with €8,000 to €30,000 or more in the UK. The price depends on whether the admission is inpatient or outpatient, how long the programme lasts, and what diagnostic tests and therapy sessions are included.
Second-generation antipsychotics are the first-line choice. Commonly used options include risperidone, aripiprazole, olanzapine and quetiapine. The choice depends on the young person's symptom profile, weight, metabolic risk and previous response. All require regular monitoring of weight, blood glucose, lipids and ECG.
An initial inpatient stabilisation stay is typically two to four weeks. The broader programme — including outpatient therapy, medication reviews and family sessions — continues for months to years. Recovery milestones such as reduced episodes and return to school usually emerge over six to twelve months.
The treatment itself is not physically painful. Some young people find the diagnostic interviews or therapy sessions emotionally difficult, particularly in the early stages. Medication side effects such as sedation or restlessness can be uncomfortable but are usually manageable with dose adjustment. Family sessions can be challenging but are structured to be supportive rather than confrontational.
Common risks include weight gain, sedation, metabolic changes (raised blood sugar and lipids) and movement-related effects. These are monitored regularly. Rare but serious risks include cardiac QTc prolongation. A psychiatrist will weigh the risks against the significant harm that untreated psychosis causes to development and functioning.
The principles are similar — medication plus psychosocial support — but young people are more sensitive to certain side effects, the diagnostic process is more complex, family involvement is essential rather than optional, and the educational and developmental consequences of untreated illness are more acute. Specialist child and adolescent psychiatrists are needed rather than adult services.
Check that there is a named child and adolescent psychiatrist, that the unit has a dedicated space for young people, that the programme includes family therapy and not just medication, and that you receive a written treatment plan before any payment. Ask for a preparatory video consultation with the lead clinician.
An intensive inpatient programme is usually two to four weeks. Some families stay for a ten- to fourteen-day intensive outpatient programme if the young person is already partially stabilised. Aftercare continues remotely, with video consultations scheduled with the Turkish team after the family returns home.